This is obviously very good news, but I wish when RVX finds these interesting subgroup results Don would throw in a line that “the treated and placebo groups were still well matched for all criteria (such as BP, cholesterol...) that could have affected the endpoint.” It leaves me feeling uneasy, because they  have the data and must have looked at it.

BT status would be great, but of course the FDA might still want another P3 to prove the claim. And for the endpoints in question, that’s not a quick fix.

Nevertheless, it’s great news that should attract the interest of BP with big pockets and an existing interest in diabetes/CVD.

I am puzzled why RVX is not making more noise about the significant reduction in CHF admissions in BETonMACE. Although this was a secondary endpoint, we know for sure the patients were well matched, and that another drug has been approved for the same effect, demonstrated as a secondary endpoint, in similar patients.